KRAS and neoplasm: – Dose of 600 mg orally administered twice daily identified for the expansion cohort – Sub-population of patients with STK11 co-occurring mutation (n=14): objective response rate of 64%. Immune transcripts (e.g., CD4 and CD8) increased after adagrasib treatment compared to baseline. – mechanistic biomarkers analyses on 3 pre- and post-treatment tumor biopsies: downregulation of K-RAS/MAPK genes including DUSP6 and SPRY4.